In Frequency Therapeutics’ quick lifetime as an organization, it’s had its ups and downs. On Tuesday, throughout an R&D occasion day, the corporate unleashed a slew of bulletins that add context to the event of a flagship listening to loss drug, and suggest some instructions.
Based in 2015, Frequency Therapeutics has targeted on a regenerative drugs strategy to listening to loss. The strategy is centered on revamping progenitor cells that finally develop into key sound-conducting hair cells within the cochlea. The irreversible disappearance or harm of those hair cells contributes to sensorineural listening to loss – the most typical kind of listening to loss.
On Tuesday, the corporate made a number of bulletins relating to its FX-322 – it’s drug candidate for listening to loss. Frequency highlighted pooled information from early trials suggesting the product has result in scientific advantages, and advised {that a} Part 2 research’s discouraging outcomes had been attributable to poor research design. Then, it unveiled a brand new listening to loss product, and a a number of sclerosis drug program.
Reforming FX-322 research design
Most circumstances of sensorineural listening to loss are handled with both cochlear implants, or with listening to aids. Individuals who expertise sudden listening to loss would possibly strive steroid remedies, but there are not any medicine authorised to deal with or reverse sensorineural listening to loss.
FX-322 bought off to an excellent begin. One Part 1b research on 15 individuals who acquired the FX-322 drug and eight individuals who bought placebo injections didn’t detect any hostile negative effects. 4 individuals who acquired the drug noticed clinically significant enchancment of their capability to listen to particular phrases.
A aspect observe: Frequency measures success of its drug based mostly on “speech notion” moderately than a capability to easily hear sounds. Different trials on cochlear implants have used this endpoint, and Chief Scientific Officer Chris Unfastened, says that the corporate has “alignment” with the FDA on the utility of measuring listening to medicine this manner.
Over time, these outcomes have held up, mentioned Carl LeBel, Frequency’s chief improvement officer. Unpublished sturdiness information from 5 individuals which have been adopted over one to 2 years discovered that three topics are nonetheless seeing statistically important enhancements, he informed Tech Crunch.
“That, to us, advised some topics are capable of preserve the profit. That profit might final a 12 months, it might final two years. We simply have to observe extra sufferers that present this enchancment, nevertheless it actually suggests a illness modifying profit,” mentioned LeBel.
However the excellent news on FX-322 has been tempered. A Part 2a scientific trial advised the system had not proven any enchancment in listening to loss in comparison with placebo.
That research was carried out on 95 individuals, half of whom acquired 4 injections of the drug, whereas the opposite half acquired placebos. There have been restricted enhancements in each teams and the corporate reported there was “no discernible profit” of the drug in that trial.
Shares of Frequency dropped from $36 to $7 the day the information was introduced, and have remained nicely under earlier highs since. In response, some shareholders have filed a class-action lawsuit claiming management misrepresented FX-322 in earnings calls, press releases, SEC filings and displays earlier than March 23, 2021.
At this level, firm management argues that this research was tainted by bias — as a result of sufferers might have underreported their very own listening to capability to achieve entry to the trial, mentioned LeBel. And the research didn’t adequately management for that chance.
“As sufferers had been coming in to the research, there have been inconsistencies between their historic speech notion scores and the scores that they had been coming into on the baseline go to of the research,” LeBel informed TechCrunch.
Jason Glashow, Frequency’s senior vice chairman of company affairs, clarified that the corporate sees this as a “design subject” with the trial.
“Whereas there may be bias within the research it’s not the fault of people that participated,” he informed TechCrunch.
In the course of the R&D day, Frequency reported pooled information from three of the Part I research to make the case that FX-322 was displaying a sample of response, and that the Part 2 research was an outlier.
Pooled information from three of Frequency Therapeutics trials on FX-322 confirmed a sample of response. A Part 2 scientific trial confirmed no impact in comparison with placebo, however management argues the research suffered from bias and poor design.
It’s unclear how this information might or might not affect the continued authorized proceedings. However the expertise has knowledgeable the development of future research on the FX-322 drug.
Frequency has already introduced the start of a brand new Part 2b scientific trial on FX-322. This research on 124 individuals included a one month “lead in” part to observe individuals’ listening to earlier than baseline listening to is measured. The primary affected person was dosed in October 2021.
It’s going to additionally slim the give attention to what kind of listening to loss the corporate is focusing on: these topics could have recognized noise-induced or sudden sensorimotor listening to loss. It’s a advantageous distinction, however barely modifications the parameters of what kinds of listening to loss the remedy targets. (Nonetheless, noise-induced listening to loss impacts between 10 and 40 million folks per 12 months, per CDC estimates).
A brand new drug candidate and MS program
Except for FX-322, Frequency is, for the primary time, seeking to wager on greater than only one product to ascertain itself. The corporate additionally has plans to check a brand new product, known as FX-345, a stronger model of the small molecule in FX-322. That efficiency, mentioned Unfastened, provides this product the flexibility to penetrate deeper into the cochlea.
The corporate might be pursuing an Investigational New Drug Software IND (IND) in Q2 of subsequent 12 months.
Frequency can be within the technique of creating a a number of sclerosis drug known as FX-162 – one other step towards one of many firm’s earlier articulated targets: to focus extra broadly on regenerative drugs.
Based on a presentation considered by TechCrunch, the corporate does have preliminary information from mouse research suggesting the drug has been capable of assist drive oligodendrocyte manufacturing. These cells produce the fatty sheath that’s degraded in sufferers with a number of sclerosis.
Nonetheless, the corporate wouldn’t disclose a timeline for upcoming research.
For now, the main focus stays on FX-322, and on the newly designed trials that may present solutions to some excellent questions.